Virological outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in antiretroviral-naive HIV-1-infected participants with baseline HIV-1 RNA ≥1,000,000 copies/ml: a post hoc analysis of Phase III clinical trials

Antivir Ther. 2018;23(1):95-99. doi: 10.3851/IMP3187.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Antiretroviral Therapy, Highly Active
  • Female
  • HIV Infections / drug therapy*
  • HIV Infections / virology*
  • HIV-1 / drug effects*
  • HIV-1 / genetics*
  • Humans
  • Male
  • Middle Aged
  • RNA, Viral*
  • Treatment Outcome
  • Viral Load*
  • Young Adult

Substances

  • Antineoplastic Agents
  • RNA, Viral